ORYZON to present further positive efficacy data from iadademstat ALICE Phase IIa trial at the 62nd Congress of the American Society of Hematology
ORYZON receives approval to start PORTICO Phase IIb trial with vafidemstat in Borderline Personality Disorder
Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes
ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders
Epigenetics is a regulatory system that controls gene expression without affecting the makeup of the genes themselves. Regulation of gene transcription and translation are key biological determinants for cellular differentiation and function, and transcriptional imbalances play a significant pathogenic role in a number of human diseases.
ORYZON is a clinical stage biopharmaceutical company that leverages epigenetics to discover and develop innovative personalized therapeutics for patients with cancers and CNS disorders. We are able to identify and validate biomarkers and therapeutic targets through our epigenetic platform and translate them into advanced and personalized therapies.